newsfilter.io

Jonathan Simons

Showing 1–5 of 5 transcripts.

  1. Milken Institute1h 0m

    Advancing Critical Health Issues for Veterans

    Jonathan Simons, Prudence Fisher, Isla Garraway, Deborah Lafer Scher, Earle Mack, Peter O'Rourke, Arock Bolanos, Christopher Seeley, Gary, Debra, Major Kent

    Hosted by Dr. Jonathan Simons of the Prostate Cancer Foundation, this panel outlines a strategic public-private partnership designed to modernize Veterans Health Administration care through precision oncology and innovative mental health interventions. Key initiatives include a $50 million commitment to establish a national network of Centers of Excellence for prostate cancer genome sequencing and a standardized equine therapy trial targeting PTSD, which leverages biofeedback mechanisms to reduce suicide risks among the 30% of veterans diagnosed with the disorder. By addressing critical infrastructure bottlenecks and utilizing the Million Veterans Program's genetic database, these collaborative models aim to create scalable, evidence-based healthcare solutions for veterans that can subsequently be extended to the broader civilian population.

  2. Milken Institute57 min

    Advancing Health Technology and Innovation

    Jonathan Simons, Chris Austin, Annalisa Jenkins, Richard Merkin, Kim Nguyen, David Spetzler

    Leading innovators and policymakers are convening to redefine healthcare delivery through a convergence of genomic editing, artificial intelligence, and cross-disciplinary collaboration rather than incremental improvements. Key figures emphasize leveraging technologies like CRISPR and deep learning to bridge the massive translation gap between molecular discovery and patient treatment, with the goal of curing rare genetic disorders and democratizing precision oncology. The discussion outlines a strategic framework for the UAE to leapfrog legacy systems by deploying high-impact solutions such as organ-on-a-chip models and AI-driven diagnostics to transform untreatable conditions into manageable outcomes within the coming decade.

  3. Milken Institute1h 0m

    Humankind vs. Cancer: The Scorecard

    Jonathan Simons, Chris Boshoff, André Choulika, Carlo Greco, Nils Lonberg, Richard Paulson, Suzanne Topalian

    Leading oncologists and industry executives convened to address the global burden of nine million annual cancer deaths by highlighting transformative breakthroughs in CAR T-cell therapy, immune checkpoint inhibitors, and precision medicine. Panelists emphasized that reducing mortality rates requires harmonizing clinical trial consent rules, shifting from empirical chemotherapy to rational drug combinations, and leveraging advanced ex vivo models to accelerate development. The consensus call to action urges a unified global strategy prioritizing early detection, patient access to novel innovations, and the removal of intellectual property barriers to eliminate the human and economic costs of cancer.

  4. Milken Institute1h 1m

    Bringing 21st Century Medicine to America's Veterans

    Jonathan Simons, Matthew Collier, Magali Haas, Matthew Rettig, Mark Simon

    The Department of Veterans Affairs has established a Senior Advisor for Strategic Partnerships to shift from isolated operations to a collaborative model leveraging its $169 billion budget and unique longitudinal data assets. By partnering with entities like Cohen Veterans Bioscience and private biotech firms, the agency is accelerating research on traumatic brain injury, suicide prevention, and precision oncology, evidenced by successful treatments for advanced prostate cancer patients. These initiatives aim to de-risk clinical trials, improve patient access to novel therapies, and transform the VA into a premier engine for precision medicine by overcoming historical cultural barriers to external collaboration.

  5. Milken Institute1h 3m

    Impatient Patients: How Disease Organizations Are Accelerating Research

    Margaret Anderson, Lou DiGennaro, Jonathan Simons, Gordon Gunn, Deborah Black, John Walsh

    Representatives from Faster Cures and five major disease-focused nonprofits outlined how venture philanthropy and patient-led activism accelerate cures by de-risking early-stage research and navigating the "Valley of Death" between discovery and clinical application. Leaders from the Leukemia and Lymphoma Society, Prostate Cancer Foundation, and the Alpha-1 Foundation detailed strategic investments that generated massive financial leverage and established critical infrastructure, such as patient registries and rapid autopsy programs, to overcome funding gaps and accelerate trial recruitment. The panel concluded that sustainable progress requires aligning academia, industry, and regulators while empowering patients to actively define research priorities and drive policy changes for faster approvals and reimbursement.